These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36388164)

  • 1. Ultrasonically Enhanced ZD2767P-Carboxypeptidase G2 Deactivates Cisplatin-Resistant Human Lung Cancer Cells.
    Liu Q; Li X; Luo Y; Wang H; Zhang Y; Yu T
    Oxid Med Cell Longev; 2022; 2022():9191233. PubMed ID: 36388164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasound Enhances ZD2767P-Carboxypeptidase G2 against Chemoresistant Ovarian Cancer Cells by Altering the Intracellular Pharmacokinetics of ZD2767D.
    Liu Q; Zhong X; Zhang Y; Li X; Qian G; Yu T
    Mol Pharm; 2020 Jun; 17(6):1922-1932. PubMed ID: 32302486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular Pharmacokinetics of Activated Drugs in a Prodrug-Enzyme-Ultrasound System: Evaluations on ZD2767P+CPG2+US.
    Yu T; Li X; Yu T; Chen M; Sun Y; Ran R
    ACS Med Chem Lett; 2024 May; 15(5):739-745. PubMed ID: 38746880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2.
    Schepelmann S; Ogilvie LM; Hedley D; Friedlos F; Martin J; Scanlon I; Chen P; Marais R; Springer CJ
    Cancer Res; 2007 May; 67(10):4949-55. PubMed ID: 17510425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767.
    Monks NR; Blakey DC; East SJ; Dowell RI; Calvete JA; Curtin NJ; Arris CE; Newell DR
    Eur J Cancer; 2002 Jul; 38(11):1543-52. PubMed ID: 12110502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material.
    Webley SD; Francis RJ; Pedley RB; Sharma SK; Begent RH; Hartley JA; Hochhauser D
    Br J Cancer; 2001 Jun; 84(12):1671-6. PubMed ID: 11401322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of Long-Acting CNGRC-CPG2 Fusion Proteins: New Derivatives to Overcome Drug Immunogenicity of Ligand-Directed Enzyme Prodrug Therapy for Targeted Cancer Treatment.
    Al-Mansoori L; Al Qahtani AD; Elsinga P; Goda SK
    Technol Cancer Res Treat; 2021; 20():15330338211057371. PubMed ID: 34802309
    [No Abstract]   [Full Text] [Related]  

  • 8. Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue.
    Monks NR; Blakey DC; Curtin NJ; East SJ; Heuze A; Newell DR
    Br J Cancer; 2001 Sep; 85(5):764-71. PubMed ID: 11531265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of ZD2767P-carboxypeptidase G2-ultrasound therapy against cisplatin-resistant cancer.
    Yu T; Li X
    Front Oncol; 2023; 13():1151613. PubMed ID: 37274240
    [No Abstract]   [Full Text] [Related]  

  • 10. Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT).
    Monks NR; Calvete JA; Curtin NJ; Blakey DC; East SJ; Newell DR
    Br J Cancer; 2000 Jul; 83(2):267-9. PubMed ID: 10901381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein.
    Bhatia J; Sharma SK; Chester KA; Pedley RB; Boden RW; Read DA; Boxer GM; Michael NP; Begent RH
    Int J Cancer; 2000 Feb; 85(4):571-7. PubMed ID: 10699932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane.
    Cowen RL; Williams JC; Emery S; Blakey D; Darling JL; Lowenstein PR; Castro MG
    Cancer Gene Ther; 2002 Nov; 9(11):897-907. PubMed ID: 12386828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.
    Francis RJ; Sharma SK; Springer C; Green AJ; Hope-Stone LD; Sena L; Martin J; Adamson KL; Robbins A; Gumbrell L; O'Malley D; Tsiompanou E; Shahbakhti H; Webley S; Hochhauser D; Hilson AJ; Blakey D; Begent RH
    Br J Cancer; 2002 Sep; 87(6):600-7. PubMed ID: 12237768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy.
    Friedlos F; Lehouritis P; Ogilvie L; Hedley D; Davies L; Bermudes D; King I; Martin J; Marais R; Springer CJ
    Clin Cancer Res; 2008 Jul; 14(13):4259-66. PubMed ID: 18594008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucarpidase (carboxypeptidase G2): Biotechnological production, clinical application as a methotrexate antidote, and placement in targeted cancer therapy.
    Moradbeygi F; Ghasemi Y; Farmani AR; Hemmati S
    Biomed Pharmacother; 2023 Oct; 166():115292. PubMed ID: 37579696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination.
    Marais R; Spooner RA; Light Y; Martin J; Springer CJ
    Cancer Res; 1996 Oct; 56(20):4735-42. PubMed ID: 8840992
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Al-Mansoori L; Bashraheel SS; Qahtani ADA; O'Connor CD; Elsinga P; Goda SK
    Oncotarget; 2020 Feb; 11(6):619-633. PubMed ID: 32110281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive detection of carboxypeptidase G2 activity in vivo.
    Jamin Y; Smyth L; Robinson SP; Poon ES; Eykyn TR; Springer CJ; Leach MO; Payne GS
    NMR Biomed; 2011 May; 24(4):343-50. PubMed ID: 20891022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug.
    Spooner RA; Martin J; Friedlos F; Marais R; Springer CJ
    Cancer Gene Ther; 2000 Oct; 7(10):1348-56. PubMed ID: 11059693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
    Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
    Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.